现实世界的数据揭示了Cangrelor的安全性是什么? 对FDA不良事件报告系统 (FAERS) 数据库的分析
Zhaojun Wang1, Junhang Zhang1, Donglei Shi1
1Department of Thoracic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Expert opinion on drug safety
|February 19, 2025
概括
这项研究使用FDA数据分析了香的不良事件 (AE). 发现了心脏骤停等意想不到的副作用,强调了需要明确的使用指南和遵守协议以提高患者安全.
科学领域:
- 药物监督 药物监督 药物监督
- 心血管医学 心血管医学
- 药品安全 药品安全
背景情况:
- 有限的现实世界安全数据存在于康格罗尔,一种药物用于预防血栓事件在穿皮冠状动脉干预期间.
- 本研究通过分析与格相关的不良事件来解决对全面安全信息的需求.
研究的目的:
- 通过美国食品和药物管理局的不良事件报告系统 (FAERS) 数据库,分析与草相关的不良事件 (AE).
- 为了确定与格雷勒使用相关的预期和意外的安全问题.
主要方法:
- 利用了FAERS数据库,包括超过1500万个病例报告.
- 采用先进的统计方法,包括报告赔率比率,比例报告比率,贝叶斯信任传播神经网络和多项马波桑收缩器.
主要成果:
- 确定了209个与龙相关的事件,在八个器官系统中出现了31个不同的不良事件.
- 非标签使用 (163次) 是最频繁报告的首选术语,与急性心肌梗塞和抗血小板/抗凝药疗法有显著关联.
- 发现了目前药物标签中未列出的意想不到的不良事件,例如心脏骤停和心力衰竭.
结论:
- 康格洛尔的安全概况包括预期和意外的不良事件.
- 确定了与产品应用相关的问题,强调制造商需要澄清说明和使用情况.
- 建议卫生保健专业人员严格遵守药物管理协议,以减轻风险.
相关概念视频
Hazard Ratio
77
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
77
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
112
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
112
Comparing the Survival Analysis of Two or More Groups
122
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
122
Censoring Survival Data
56
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
56
Introduction To Survival Analysis
162
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
162
Cancer Survival Analysis
321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321


